Mr. Trevor Broadt, MS Senior Manager, Product Release and Stability Testing Biopharmaceutical Development Program, SAIC-Frederick, Inc. Biosketch

Mr. Trevor Broadt has worked in the biotechnology field since 1992 and is currently the Senior Manager for Release and Stability Testing as well as the QC Molecular Biology Manager for the National Cancer Institute’s Biopharmaceutical Development Program (BDP) located at Fort Detrick, Maryland. The BDP develops, manufactures, and tests phase I and phase II therapeutics for cancer, AIDS, and bio-defense applications. He previously managed the Modifying & Restriction Enzymes Manufacturing and Quality Control groups at Invitrogen - Life Technologies, Inc., an ISO-certified research products company located in Frederick, Maryland.

The Biopharmaceutical Development Program (http://wwwbdp.ncifcrf.gov/index.cfm) located at Fort Detrick, was established in 1993 to provide cutting-edge development of monoclonal antibodies, recombinant proteins, peptide and DNA vaccines, virus vaccines, oncolytic viruses, gene therapy products, and manufacturing processes generally considered too novel by corporate pharma. With little public fanfare, and an even smaller budget, the BDP has advanced the state of the art in new cancer, AIDS, and bio-defense therapeutics, ultimately placing several successful products with commercial manufacturers once the proof-of-principle was established. The BDP is an FDA registered, CGMP-compliant facility that provides complete support from feasibility through development, manufacturing, testing, and filing of regulatory documentation with the FDA, and EMEA (EU). Since its inception, the BDP has completed over 100 projects, of which 69 have gone into early phase clinical trials, with more than 10 projects having already demonstrated clinical efficacy, some resulting in dramatic long-term remission.

Mr. Broadt is slowly earning PhD’s in Biochemical Engineering and Public Health. He received his MS degree in Applied Molecular Biology at the University of Maryland, Baltimore County in 1996 while working with Athena Environmental Sciences. Following the receipt of his Master’s degree he joined Life Technologies’ Nucleic Acids Quality Control group in Frederick, Maryland and later managed the $183M annual revenue Enzymes group at LTI. He made significant direct contributions to the improved manufacture and testing of over 250 molecular biology products, including Taq DNA polymerase, forensic testing products, restriction enzymes, and numerous competent cell strains. Mr. Broadt has co-authored several publications, most recently in Molecular Therapy (in press), the American Journal of Obstetrics and Gynecology (4/2007), BioProcessing Journal (Winter 2005), and Biotechnology Progress (2/2005).

« Go Back